Associated Papers
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Branford S et al.
Blood, 2009
BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Kwan TK et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi, 2009
Select a paper to view details